Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $7.6300 (-3.42%) ($7.6300 - $7.6300) on Fri. Mar. 5, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.7% (three month average) | RSI | 22 | Latest Price | $7.6300(-3.42%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.9% a day on average for past five trading days. | Weekly Trend | HTBX declines -11.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(41%) XBI(40%) ARKK(36%) IBB(35%) ACES(34%) | Factors Impacting HTBX price | HTBX will decline at least -4.35% in a week (0% probabilities). VIXM(-25%) VXX(-22%) UUP(-16%) IGOV(-12%) XLU(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.35% (StdDev 8.7%) | Hourly BBV | -0.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $9.13 | 5 Day Moving Average | $8.01(-4.74%) | 10 Day Moving Average | $8.15(-6.38%) | 20 Day Moving Average | $9.13(-16.43%) | To recent high | -39.2% | To recent low | 45.1% | Market Cap | $839m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |